Major Depressive Disorder
📧 Sign up to get email alerts when something new happens for Major Depressive Disorder.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2021-09-08FDA Approved: ESCITALOPRAM — Supplemental Application (Sun Pharmaceutical Industries, Inc.)
The FDA approved a supplemental application for escitalopram oxalate from Sun Pharmaceutical Industries, Inc., indicating approval of a gene…
-
CLINICAL_TRIALS trial_result · 2021-09-05Clinical Trial Update: Adaptive Design Study of NEST sTMS in Subjects With Major Depressive Disorder [NA]
A completed adaptive design study of NEST sTMS for Major Depressive Disorder with results posted in 2021.
-
FDA approval · 2021-09-03FDA Approved: VENLAFAXINE — Supplemental Application (Cadila Pharmaceuticals Limited)
FDA approved a supplemental application for Venlafaxine from Cadila Pharmaceuticals Limited.
-
FDA approval · 2021-09-03FDA Approved: VENLAFAXINE — Supplemental Application (Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.)
FDA approved a supplemental application for venlafaxine (generic) from Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc., approv…
-
FDA approval · 2021-09-03FDA Approved: PAROXETINE — Original Application (ANI Pharmaceuticals, Inc.)
ANI Pharmaceuticals received FDA approval for an original ANDA application for paroxetine, a generic antidepressant.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2021-09-02FDA Approved: VENLAFAXINE — Supplemental Application (Sun Pharmaceutical Industries, Inc.)
FDA approved a supplemental application for venlafaxine by Sun Pharmaceutical Industries, Inc.
-
FDA approval · 2021-09-01FDA Approved: FLUOXETINE HYDROCHLORIDE — Supplemental Application (Dr.Reddy's Laboratories Limited)
FDA approved a supplemental application for fluoxetine hydrochloride from Dr. Reddy's Laboratories Limited (ANDA 078572), updating regulator…
-
FDA approval · 2021-08-31FDA Approved: FLUOXETINE — Supplemental Application (Saptalis Pharmaceuticals, LLC.)
FDA approved a supplemental application for fluoxetine from Saptalis Pharmaceuticals, confirming the availability of a generic fluoxetine pr…
-
FDA approval · 2021-08-27FDA Approved: FLUOXETINE — Supplemental Application (PAI Holdings, LLC dba PAI Pharma)
FDA approved a supplemental application for a fluoxetine hydrochloride generic product from PAI Holdings (PAI Pharma). This action approves …
-
FDA approval · 2021-08-27FDA Approved: PAROXETINE — Original Application (Modavar Pharmaceuticals LLC)
FDA approved a generic paroxetine tablet product from Modavar Pharmaceuticals LLC under an original abbreviated new drug application (ANDA 2…
-
CLINICAL_TRIALS trial_result · 2021-08-26Clinical Trial Update: Simvastatin as an Augmentation Treatment for Treatment Resistant Depression: Randomized Controlled Trial. [Phase 3]
Phase 3 randomized controlled trial evaluating simvastatin as an augmentation therapy for treatment resistant depression and major depressiv…
-
FDA approval · 2021-08-25FDA Approved: FLUOXETINE — Supplemental Application (Dr.Reddy's Laboratories Limited)
The FDA approved a supplemental application for Fluoxetine from Dr. Reddy's Laboratories Limited.
-
FDA approval · 2021-08-23FDA Approved: CLOMIPRAMINE HYDROCHLORIDE — Supplemental Application (Northstar Rx LLC.)
FDA approved a supplemental application for clomipramine hydrochloride from Northstar Rx LLC., enabling the generic product's continued regu…
-
CLINICAL_TRIALS withdrawal · 2021-08-20Clinical Trial Update: Study Evaluating Effexor XR in Chinese Subjects With Major Depressive Disorder [Phase 4]
Phase 4 trial evaluating Effexor XR in Chinese subjects with major depressive disorder has been withdrawn.
-
CLINICAL_TRIALS trial_result · 2021-08-19Clinical Trial Update: Treating Hearing Loss to Improve Mood and Cognition in Older Adults [Phase 4]
Phase 4 clinical trial evaluating treatment for hearing loss and its effects on mood and cognition in older adults has completed with posted…
-
CLINICAL_TRIALS trial_result · 2021-08-18Clinical Trial Update: Community Study of Outcome Monitoring for Emotional Disorders in Teens [NA]
Clinical trial update for a community study monitoring emotional disorders in teens, focusing on depression and anxiety; study completed wit…
-
FDA approval · 2021-08-16FDA Approved: MIRTAZAPINE — Supplemental Application (Aurobindo Pharma Limited)
FDA approved a supplemental application for a generic Mirtazapine product from Aurobindo Pharma Limited, enabling continued marketing of an …
-
CLINICAL_TRIALS trial_result · 2021-08-10Clinical Trial Update: Accelerated Intermittent Theta Burst Stimulation for Depressive Symptoms [NA]
Clinical trial update for accelerated intermittent theta burst stimulation in depressive symptoms; study completed with results posted.
-
FDA approval · 2021-08-06FDA Approved: VENLAFAXINE HYDROCHLORIDE — Original Application (Epic Pharma, LLC)
FDA approved the original application for Venlafaxine hydrochloride (generic) manufactured by Epic Pharma, LLC.
-
FDA approval · 2021-08-04FDA Approved: CLOMIPRAMINE HYDROCHLORIDE — Original Application (Alembic Pharmaceuticals Inc.)
The FDA approved Alembic Pharmaceuticals' generic clomipramine hydrochloride through an original ANDA.
-
FDA approval · 2021-08-03FDA Approved: ESCITALOPRAM OXALATE — Supplemental Application (Camber Pharmaceuticals, Inc.)
FDA approved Camber Pharmaceuticals' supplemental application for escitalopram oxalate, a generic antidepressant product. This constitutes a…
-
CLINICAL_TRIALS trial_result · 2021-07-26Clinical Trial Update: An Evaluation of AXS-05 for the Treatment of TRD in Treatment-Adherent Patients [Phase 2]
Phase 2 clinical trial evaluating AXS-05 for treatment-resistant depression in treatment-adherent patients.
-
CLINICAL_TRIALS trial_result · 2021-07-26Clinical Trial Update: Improving Student Mental Health: Adaptive School-based Implementation of CBT [NA]
Completed clinical trial evaluating adaptive school-based implementation of CBT for depression and anxiety in students.
-
FDA approval · 2021-07-23FDA Approved: DRIZALMA SPRINKLE — Supplemental Application (SUN PHARMACEUTICAL INDUSTRIES, INC.)
The FDA approved a supplemental application for Drizalma Sprinkle, a duloxetine product, expanding the label to include a sprinkle-form dosa…
-
CLINICAL_TRIALS trial_result · 2021-07-16Clinical Trial Update: A Long Term Study of ALKS 5461 in the Treatment of Refractory Major Depressive Disorder (MDD) [Phase 3]
Phase 3 trial of ALKS 5461 for refractory major depressive disorder was terminated; results posted in 2021.